Across TCGA pan-cancer cohorts, NAT1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NAT1 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher NAT1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
READ and UCEC are the cancer types where NAT1 Mutation most reproducibly stratifies survival.